Possible alternative strategy for stageI imatinib-sensitive testicular seminoma; lessons from a case associated with Philadelphia chromosome-positive acute lymphoblastic leukemia

Annals of Oncology

Volumn 21, Issue 5, 2010, Pages 1129-1130

  Okamura, A ^a   Wakahashi, K ^a   Ishii, S ^a   Katayama, Y ^a   Yamamoto, K ^a   Matsui, T ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD19 ANTIGEN; CD34 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN; IMATINIB; LACTATE DEHYDROGENASE; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; CASE REPORT; CORD BLOOD STEM CELL TRANSPLANTATION; DISSEMINATED INTRAVASCULAR CLOTTING; FOLLOW UP; HUMAN; LETTER; LOW BACK PAIN; MALE; ORCHIECTOMY; PANCYTOPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SEMINOMA; TESTICULAR ENLARGEMENT; TUMOR REGRESSION;

EID: 77953342977     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp607     Document Type: Letter

References (5)

1. Went PT, Dirnhofer S, Bundi M et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22: 4514-4522.
2. Kemmer K, Corless CL, Fletcher JA et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305-313.
3. Stoop H, Honecker F, van de Geijin GJM et al. Stem cell factor as a novel diagnostic marker for early malignant germ cells. J Pathol 2008; 216: 43-54.
4. Pedersini R, Vattemi E, Mazzoleni G et al. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007; 8: 1039-1040.
5. Einhorn LH, Brames MJ, Heinrich MC et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006; 29: 12-13.